- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Why Did Edgewise Therapeutics Jump 25%+ On Wednesday? | 1 | Forbes | ||
| Do | Why Edgewise Therapeutics Stock Rocked the Market Today | 5 | The Motley Fool | ||
| Mi | Edgewise Therapeutics Shares Surge 20% On Positive Phase 2 HCM Trial Update | - | RTTNews | ||
| Mi | Edgewise rises on mid-stage trial data for heart disease therapy | 1 | Seeking Alpha | ||
| Mi | Why Is Edgewise Therapeutics Stock Soaring Wednesday? | 2 | Benzinga.com | ||
| Mi | Edgewise meldet positive Sicherheitsdaten für Herzmedikament EDG-7500 | 3 | Investing.com Deutsch | ||
| EDGEWISE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Edgewise reports positive interim safety data for HCM drug EDG-7500 | 1 | Investing.com | ||
| Mi | Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy | 1.257 | PR Newswire | - In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver... ► Artikel lesen | |
| 02.12. | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | 120 | PR Newswire | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| 20.11. | Edgewise Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | 167 | PR Newswire | BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| 10.11. | Edgewise Therapeutics Names Michael Nofi New CFO As Michael Carruthers Retires | 9 | RTTNews | ||
| 10.11. | Edgewise Therapeutics announces appointment of Michael Nofi as CFO | 3 | Seeking Alpha | ||
| 10.11. | Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers | 166 | PR Newswire | BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics... ► Artikel lesen | |
| 06.11. | Edgewise Therapeutics GAAP EPS of -$0.39 beats by $0.01 | 6 | Seeking Alpha | ||
| 06.11. | Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 210 | PR Newswire | - Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch -
- ... ► Artikel lesen | |
| 06.11. | Edgewise Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Edgewise Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11. | Truist Securities bekräftigt "Buy"-Rating für Edgewise Therapeutics vor wichtigen Studiendaten | 12 | Investing.com Deutsch | ||
| 03.11. | Truist Securities reiterates Buy rating on Edgewise Therapeutics stock | 1 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,50 | -0,56 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| EVOTEC | 5,388 | +3,10 % | Eilmeldung am Abend: EVOTEC SE zündet +3,10?% Rakete! | ||
| BB BIOTECH | 49,200 | -0,10 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,025 | +16,67 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 45,370 | -0,33 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 4,310 | 0,00 % | Morgen-Update: Curevac-Aktie auf Höhenflug - Anleger feiern starkes Comeback! | ||
| MODERNA | 31,200 | -4,73 % | Nvidia Rises, Moderna and Brown-Forman Slump, and More | ||
| VALNEVA | 3,654 | -1,77 % | Morgen-Update: Valneva-Aktie explodiert - Anleger im Kaufrausch! | ||
| AMGEN | 332,93 | -0,31 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| NOVAVAX | 6,830 | -1,58 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 354,23 | -0,15 % | Stryker Earnings Preview: What to Expect | ||
| BIOGEN | 177,11 | +0,44 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,310 | -0,43 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 55,06 | -2,91 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| 4SC | 0,086 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen |
Das Unternehmen EDGEWISE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,41 % bei einem Aktienkurs von 26,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EDGEWISE THERAPEUTICS INC finden Sie auf Wallstreet Online.